title: Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells.
abstract: In order to enhance the therapeutic efficacy and intracellular concentration of bevacizumab (BVC), we have designed a novel tumor endothelial marker 1 (TEM1)/endosialin (Ab-/scFv)-conjugated mesoporous silica nanoparticles (MSN) to target ovarian cancer cell. The Ab-/scFv-conjugated MSN were prepared by the conjugation of amine functional group of antibody of the carboxyl group of MSN. The resultant MSN was nanosized, spherical shaped, and exhibited a controlled release phenomenon in pH 7.4 conditions. Furthermore, BMSN/Ab was found to increase the cellular uptake and intracellular distribution of BVC in OVCAR-5 cancer cells. The Ab- conjugated MSN exhibited a superior anticancer effect with profound apoptosis in cancer cells in a time- and concentration dependent manner. Consistently, BMSN/Ab effectively inhibited the colony formation in transwell plate. Finally, BMSN/Ab showed a notable increase in the proportion of cells in G2/M phase of cell cycle indicating promising anticancer efficacy profile. Overall, Ab-/scFv-conjugated MSN might provide an effective strategy for the therapeutic management of ovarian cancers.
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China; School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong 250022, PR China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China; School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong 250022, PR China.
authors.forename: Jing
authors.initials: J
authors.lastname: Guo
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China.
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Zhang
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China.
authors.forename: Da-Peng
authors.initials: DP
authors.lastname: Li
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China.
authors.forename: Ting-Ting
authors.initials: TT
authors.lastname: Zhang
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China.
authors.forename: Fu-Feng
authors.initials: FF
authors.lastname: Gao
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China.
authors.forename: Nai-Fu
authors.initials: NF
authors.lastname: Liu
authors.affiliation: Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, PR China. Electronic address: shengxiugui@hotmail.com.
authors.forename: Xiu-Gui
authors.initials: XG
authors.lastname: Sheng
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007128:Immunoglobulin Fragments / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010316:Particle Size; D012822:Silicon Dioxide / Q000737:chemistry*
chemical_list: D020533:Angiogenesis Inhibitors; D007128:Immunoglobulin Fragments; D000068258:Bevacizumab; D012822:Silicon Dioxide
keywords: Antibody; Apoptosis; Bevacizumab; Mesoporous silica nanoparticles; Ovarian cancer